Carestream Continues Drive to Improve Image Quality and Workflow With 45 Patents in 2021

Carestream Health was awarded 45 new patents in 2021 for global advances in artificial intelligence (AI), digital radiography (DR) workflow and detectors as well as other healthcare imaging technology areas.

Twenty-three of the patents were awarded by the U.S. Patent and Trademark Office, while an additional 22 patents were received in European and Asian countries.

“Carestream continuously strives to deliver cutting-edge technologies worldwide, and these patents demonstrate our commitment to meet the evolving needs of providers and patients alike,” said Eugene Shkurko, Intellectual Property Counsel at Carestream. “Our research and development teams are always focused on enabling better diagnoses and enriching patient care with critical innovations such as lowering radiation dose without sacrificing our standards in image quality, and optimizing provider workflow with AI.”

Patents earned by Carestream’s scientists and engineers in 2021 include:

  • New medical image capture technologies with AI that help remove undesired bony structures from X-ray images to increase image clarity
  • Technology advances in image capture that automate positioning of the X-ray source according to the exam entered by the radiographer; and
  • A patent for X-ray detectors with stepped edges that fit together so that the combined detectors can be used for long-length imaging.

Carestream’s growing product portfolio includes 2D and 3D digital medical imaging technology for general radiology and specialty areas such as pediatrics and fluoroscopic surgical imaging, along with digital laser imagers that output medical images to film. These technologies fit budget, workflow, safety and space requirements of imaging facilities worldwide.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”